Across TCGA pan-cancer cohorts, IGHV4-61 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGHV4-61 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGHV4-61 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV4-61 expression acts as an unfavorable survival marker.
LIHC, ACC, and STAD are the cancer types where IGHV4-61 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.